Patents Assigned to SLBIGEN INC.
  • Publication number: 20220401518
    Abstract: A recombinant lentiviral vector includes a gene encoding a hepatocyte growth factor (HGF) protein. And a cell that is transfected with the lentivirus produced by using the vector is provided. The recombinant lentivirus includes a gene encoding a HGF protein, and a host cell transfected with the lentivirus maintains a high cell proliferation rate. Thus, a mesenchymal stem cell expressing HGF by being transfected with the lentivirus may be usefully employed as a cell therapeutic agent.
    Type: Application
    Filed: June 29, 2022
    Publication date: December 22, 2022
    Applicant: SLBIGEN INC.
    Inventors: Young Chul SUNG, Soon Min Lee, Hey-yon Kim
  • Publication number: 20220401491
    Abstract: A recombinant lentiviral vector containing a gene encoding a TRAIL protein and a CD protein; and a cell that is transfected with the lentivirus produced by using the vector. A host cell transfected with the recombinant lentivirus maintains a high cell proliferation rate and overexpresses a TRAIL protein and a CD protein. Thus, a mesenchymal stem cell transfected with the lentivirus may be usefully employed as a cell therapeutic agent.
    Type: Application
    Filed: June 29, 2022
    Publication date: December 22, 2022
    Applicant: SLBIGEN INC.
    Inventors: Young Chul SUNG, Soon Min LEE, Hey-yon KIM
  • Publication number: 20210155663
    Abstract: The present invention relates to; a recombinant lentivirus comprising a gene encoding brain-derived neurotrophic factor (BDNF) protein; and a mesenchymal stem cell transformed with the lentivirus; and a method for mass-producing a cell therapeutic agent expressing BDNF protein using the same. The mesenchymal stem cell transformed with the recombinant lentivirus of the present invention can regulate the timing of expression of BDNF protein, maintain a high cell proliferation rate and overexpress a BDNF protein, and are excellent in safety. Therefore, a mesenchymal stem cells transfected with the lentivirus may be used for the treatment of various neurological diseases as a stein cell therapeutic agent capable of being mass-produced and maintaining the same effect.
    Type: Application
    Filed: January 24, 2019
    Publication date: May 27, 2021
    Applicant: SLBIGEN INC.
    Inventors: Young Chul SUNG, Soon Min LEE, Hey Yon KIM
  • Publication number: 20190038717
    Abstract: A recombinant lentiviral vector includes a gene encoding a hepatocyte growth factor (HGF) protein. And a cell that is transfected with the lentivirus produced by using the vector is provided. The recombinant lentivirus includes a gene encoding a HGF protein, and a host cell transfected with the lentivirus maintains a high cell proliferation rate. Thus, a mesenchymal stem cell expressing HGF by being transfected with the lentivirus may be usefully employed as a cell therapeutic agent.
    Type: Application
    Filed: February 6, 2017
    Publication date: February 7, 2019
    Applicant: SLBIGEN INC.
    Inventors: Young Chul SUNG, Soon Min LEE, Hey-yon KIM
  • Publication number: 20190038676
    Abstract: The present invention relates to: a recombinant lentiviral vector comprising a gene encoding a TRAIL protein and a CD protein; and a cell that is transfected with the lentivirus produced by using the vector. A host cell transfected with the recombinant lentivirus of the present invention maintains a high cell proliferation rate and overexpresses a TRAIL protein and a CD protein. Thus, a mesenchymal stem cell transfected with the lentivirus may be usefully employed as a cell therapeutic agent.
    Type: Application
    Filed: February 6, 2017
    Publication date: February 7, 2019
    Applicant: SLBIGEN INC.
    Inventors: Young Chul SUNG, Soon Min LEE, Hey-yon KIM